Aerie’s glaucoma drug journey ends in $770M sale to Alcon

Alcon has agreed to acquire Aerie Pharmaceuticals for about $770 million, betting its sprawling commercial presence can boost the uptake of the biotechnology company’s two glaucoma drugs.